SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Oxford GlycoSciences Plc
An SI Board Since January 2000
Posts SubjectMarks Bans
469 13 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
344Self-assembly of proteins and their nucleic acids Research Self-assembly of prJohn McCarthy-2/19/2003
343OT Never looked at them. Do they still have the (discounted) Tularik shares? scaram(o)uche-2/19/2003
342DJ Oxford Glycosciences May Become Object of Bidding War By Susannah RodgersWard Knutson-2/18/2003
341(OT) Actually, I like Protherics a lot. Cap. is around £35m, and they forecnigel bates-2/18/2003
340<i>I would like a better deal, however</i> As an OGS shareholder, Inigel bates-2/18/2003
339Maybe the less attractive cash bidders could do something spicy, like spinning oscaram(o)uche-2/17/2003
338<i>A cash bid from CLL would be a real disappointment, IMO</i> ...unigel bates-2/17/2003
337<i>OGS shares rise as Celltech considers bid Shares in Oxford GlycoSciencnigel bates-2/17/2003
336Celltech making an offer? biz.yahoo.comThe Dodgy Ticker-2/15/2003
335sorry, I lumped it with MorphoSys, assuming that there was an equity stake in thscaram(o)uche-2/14/2003
3340%? I'm confused???keokalani'nui-2/14/2003
333What percentage of Crucell do we (will we) own?scaram(o)uche-2/14/2003
332Message 18572690 and, nothing shockingly new, but there's also this....... scaram(o)uche-2/12/2003
331Accelrys To Provide Technology For Functional Annotation of Confirmant's Proscaram(o)uche-2/11/2003
330J Immunol 2003 Jan 15;170(2):711-8 Program Death-1 Engagement Upon TCR Activatscaram(o)uche-2/6/2003
329Sorry about the formatting, from today's 6-K...... 3. Background to and reascaram(o)uche-2/3/2003
328Will CAT sweeten the deal - or will they walk away if necessary (as they did witnigel bates-1/30/2003
327This week's BioCentury, page one........ <i>With the merger plans of scaram(o)uche-1/28/2003
326Hepatology 2003 Jan;37(1):87-95 Activated stellate cells express the TRAIL recscaram(o)uche-1/25/2003
325Gene Ther 2003 Jan;10(1):59-71 Novel antisense oligonucleotides targeting TGF-bscaram(o)uche-1/25/2003
324An absolutely great merger, IMO. However, it increases my risk, and the deal shscaram(o)uche-1/23/2003
323<i>"CAT is issuing shares and getting cash and technology of dubious keokalani'nui-1/23/2003
322OGS biggest shareholders include Fidelity with 11.45% (largely acquired in Aprilnigel bates-1/23/2003
321More comment. Mr Keegan doesn't seem too bright; I'm not sure how cash nigel bates-1/23/2003
320From CAT annual report (can't get it to format, so I have cut some stuff outnigel bates-1/23/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News